The identification of several leukemia-associated antigens (LAAs), including RHAMM, which induce humoral immune responses in acute and chronic myeloid leukemia, underscores the feasibility of such immunotherapeutic strategies [103]. Here, HMMR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.